# reload+after+2024-01-22 04:44:41.504598
address1§1111 Kane Concourse
address2§Suite 301
city§Bay Harbor Islands
state§FL
zip§33154
country§United States
phone§781 652 4500
website§https://www.fortressbiotech.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
fullTimeEmployees§187
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Lindsay Allan Rosenwald', 'age': 68, 'title': 'Executive Chairman, President & CEO', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 942778, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael S. Weiss Esq.', 'age': 57, 'title': 'Vice Chairman & Executive Vice Chairman of Strategic Development', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 167918, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Jin', 'age': 32, 'title': 'CFO & Head of Corporate Development', 'yearBorn': 1991, 'fiscalYear': 2022, 'totalPay': 976962, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. George C. Avgerinos', 'age': 69, 'title': 'Senior Vice President of Biologics Operations', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 386488, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Samuel  Berry', 'title': 'General Counsel & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§10
compensationRisk§5
shareHolderRightsRisk§4
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.043
priceToSalesTrailing12Months§0.71762365
currency§USD
dateShortInterest§1702598400
forwardEps§-3.68
pegRatio§-0.01
exchange§NCM
quoteType§EQUITY
shortName§Fortress Biotech, Inc.
longName§Fortress Biotech, Inc.
firstTradeDateEpochUtc§1321540200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7e5b26dc-ebdf-31b9-af0f-998270b68658
gmtOffSetMilliseconds§-18000000
targetHighPrice§75.0
targetLowPrice§10.0
targetMeanPrice§40.0
targetMedianPrice§37.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§0.827
grossMargins§-1.5089
ebitdaMargins§0.0
trailingPegRatio§None
